Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma.
Marc WehrliSamantha GuinnFilippo BirocchiAdam KuoYi SunRebecca C LarsonAntonio J AlmazanIrene ScarfoAmanda A BouffardStefanie R BaileyPraju Vikas AnekalPaula Montero LlopisLinda T NiemanYuhui SongKatherine H XuTrisha R BergerMichael C KannMark B LeickHarrison SilvaDiego Salas-BenitoTamina KienkaKorneel GrauwetTodd D ArmstrongRui ZhangQingfeng ZhuJuan FuAndrea SchmidtsFelix KorellMax JanBryan D ChoiAndrew S LissGenevieve Marie BolandDavid Tsai TingRichard Andrew BurkhartRussell William JenkinsLei ZhengElizabeth D ThompsonJacquelyn W ZimmermanMarcela V MausPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
CAR-TEAM cells enable modification of tumor stroma, leading to increased elimination of PDAC tumors. This approach represents a promising treatment option for pancreatic cancer.